NMN Supplement Research 2026: Muscle, Liver, Eyes & Why NMN Beats NR

---

What Is NMN and Why Does It Matter for Aging?

NAD+ (nicotinamide adenine dinucleotide) is one of the most important molecules in the human body. It functions as a coenzyme — essentially a molecular fuel — that powers hundreds of enzymatic reactions, including DNA repair, energy metabolism, and the activation of sirtuins (proteins strongly linked to healthy aging).

The problem is that NAD+ levels drop significantly with age. By the time most people reach their 60s, NAD+ levels in key tissues can be less than half of what they were in their 30s. This decline is now understood to be a significant driver of biological aging — contributing to mitochondrial dysfunction, inflammation, insulin resistance, and loss of tissue repair capacity.

NMN (nicotinamide mononucleotide) is a direct biological precursor to NAD+. When you consume NMN, your body converts it into NAD+, replenishing what age has depleted. Because of this, NMN has attracted serious scientific attention as a potential longevity supplement — and as of 2026, the research is starting to deliver genuinely useful answers.

---

NMN vs. NR: Why Older and Obese Adults May Need NMN Directly

Source study: Lapatto et al. (2026), International Journal of Obesity — University of Helsinki, Finland

For years, NMN and NR (nicotinamide riboside) have been competing in the NAD+ precursor supplement market. Both can raise NAD+ levels. The question that has lacked a clear answer is: does it matter which one you take?

A 2026 study from the University of Helsinki offers the most compelling answer yet — at least for two specific populations: older adults and people with obesity.

What the Researchers Did

The Finnish team analyzed fat tissue samples from identical twins. To examine obesity's effects, they compared leaner twins to their heavier sibling (average age: 46). To examine aging's effects, they compared younger participants (average age: 30) to older participants (average age: 65). By measuring mRNA — which reflects gene activity — they mapped out exactly how obesity and aging alter the NAD+ production machinery in fat tissue.

The Key Finding: The NRK1 Enzyme Problem

In both obese and older adults, the gene for NRK1 was significantly downregulated. NRK1 is the enzyme responsible for converting NR into NMN inside cells. When NRK1 activity is reduced, NR cannot efficiently complete that conversion step — which means less NMN gets made, and therefore less NAD+.

This creates a meaningful distinction. NMN does not require NRK1 to begin the pathway to NAD+. It enters cells one step closer to the final product. For people with healthy NRK1 levels (generally, younger and leaner adults), NR and NMN may work comparably well. But for the two populations most likely to be taking NAD+ supplements in the first place — older adults and those with obesity — NMN may have a more direct route to raising NAD+.

An additional finding: in obese adults specifically, NMNAT — the enzyme that converts NMN into NAD+ — was also reduced. This means that even NMN faces some conversion resistance in obese fat tissue. No single precursor is a silver bullet.

What Else Was Altered

The study also found reductions in sirtuin-1 and sirtuin-3 in obese tissue — both linked to inflammation and mitochondrial dysfunction. Sirtuin-5, involved in metabolic regulation, was reduced in both aging and obesity. CD38, an enzyme that actively breaks down NAD+ and is considered a major driver of age-related NAD+ depletion, was elevated in older adults as expected.

The heavier twins had 65% more subcutaneous fat, double the abdominal fat, and 360% more liver fat than their leaner counterparts — with corresponding gene alterations in NAD+ metabolism.

What This Means in Practice

This study doesn't definitively prove NMN is always superior to NR. What it does show is that in older and obese adults — the exact populations most likely seeking longevity supplements — the enzymatic machinery needed to convert NR into usable NAD+ is compromised. That's a meaningful factor when selecting a supplement.

Bottom line: For younger, lean adults, NR may work just as well as NMN. For older adults or those carrying excess weight, NMN's more direct pathway to NAD+ may offer a real advantage.

---

NMN and Dry Eye: A Surprising Window Into Systemic Aging

Source study: Hamada et al. (2026), preprint — Kyoto University, Japan

Dry eye affects a significant proportion of people over 60. Most people dismiss it as a minor annoyance. But a 2026 study from Kyoto University suggests it may actually be a visible symptom of the same NAD+ depletion and inflammation cycle that drives aging across multiple organ systems.

The Meibomian Gland and NAD+ Deficiency

Dry eye's most common age-related cause is dysfunction of the meibomian glands — tiny oil-secreting glands within the eyelids. When these glands atrophy, they stop producing the oily layer that keeps the tear film stable and the eye surface lubricated.

The Kyoto researchers traced this dysfunction to a specific NAD+-dependent enzyme called Hsd3b6, which produces the hormones that maintain meibomian cell function. When NAD+ levels drop, Hsd3b6 can't do its job — and meibomian glands start to deteriorate.

The CD38 Vicious Cycle

When meibomian gland function declines, local inflammation increases. That inflammation recruits immune cells equipped with CD38 — an enzyme that actively breaks down both NAD+ and NMN. More CD38 means less NAD+. Less NAD+ means worse meibomian function. Worse meibomian function means more inflammation. The cycle continues.

The Kyoto team confirmed this isn't just theoretical: in human eyelid tissue samples, adults in their mid-80s had significantly higher CD38 activity than adults in their 30s and 40s. The same vicious cycle observed in mice appears to operate in human tissue.

What NMN and 78c Did

When researchers injected 78c — a small molecule CD38 inhibitor — into the eyelids of aged mice, it raised NAD+ levels and counteracted meibomian gland atrophy. When they combined 78c with NMN, the effect was substantially greater: higher NAD+ levels and larger, healthier meibomian glands than either treatment achieved alone.

This synergy matters. Blocking NAD+ breakdown while simultaneously replenishing NAD+ precursors may be more effective than either approach on its own — a principle with implications well beyond dry eye.

The Broader Implication

This was a mouse study using direct injection — not an oral supplement trial. But the model is compelling: the same NAD+/CD38/inflammation loop observed in dry eye likely operates across multiple aging tissues, including heart muscle, the brain, and the liver.

The takeaway: Dry eye in older adults may be a canary in the coal mine for systemic NAD+ depletion. And the combination of NAD+ precursors with CD38 inhibition represents one of the more scientifically grounded approaches to combating the root causes of multiple age-related conditions.

---

What Human Trials Actually Show: Muscle, Liver, and More

Source study: Wang et al. (2025), Current Pharmaceutical Biotechnology — Wuhan University, China

Animal studies are encouraging but not conclusive. A 2025 systematic review and meta-analysis from Wuhan University gathered all randomized controlled trials pertinent to NMN's effects on muscle and liver function in middle-aged and elderly adults. The analysis covered 13 trials from 9 studies, totaling 412 participants, with NMN doses ranging from 250 to 1,250 mg/day over 4 to 24 weeks.

Walking Speed and Physical Function

Based on 8 trials, NMN supplementation significantly increased gait (walking) speed. The effect was especially pronounced in adults under 60, where improvements were roughly double those seen in older participants. Grip strength did not improve across most age groups, with a modest exception in adults over 60.

A separate Japanese clinical trial (2024) added important nuance: NMN didn't dramatically increase walking speed, but it prevented the decline in gait speed observed in the placebo group. Maintaining physical capacity as people age is one of the strongest predictors of long-term health and independence.

Liver Health: The ALT Finding

Of the six trials that measured ALT (alanine aminotransferase) — a primary marker of liver stress and injury — NMN supplementation produced a statistically significant reduction. This suggests NMN may support liver health in aging adults. The benefit was more pronounced when NMN was taken for less than 10 weeks or in participants under 60.

Insulin Resistance

Across 4 trials, NMN did not significantly improve insulin resistance when all doses were pooled. However, a sub-analysis found that doses of 300 mg or less showed meaningful improvement in insulin sensitivity. Higher doses did not — raising the counterintuitive possibility that lower NMN doses may be more effective for metabolic outcomes specifically.

A Harvard Medical School trial testing 2 grams of NMN in overweight middle-aged adults found no improvement in insulin resistance, liver enzymes, or muscle function — supporting the idea that high-dose NMN is not automatically better.

Overall Conclusion

The Wuhan University authors concluded NMN shows "encouraging" results as an anti-aging treatment and described it as safe for addressing aging in middle-aged and elderly populations. They also acknowledged the limitations honestly: studies were small, heterogeneous, and short-term. What the data consistently supports is that NMN reliably raises blood NAD+ levels, and several measurable health markers improve alongside that increase.

---

How Much NMN? What the Dosage Data Suggests

One of the most practically useful findings from current research is that dose matters — and not always in the direction you'd expect.

• For insulin sensitivity and metabolic health: 300 mg or less appears most effective. The Harvard study's 2-gram dose showed no metabolic benefit.
• For physical performance: A 6-week RCT with athletes showed dose-dependent improvements in aerobic capacity at 300, 600, and 1,200 mg/day. For walking speed, the 900 mg group showed the best median performance improvements in the largest NMN trial to date.
• For NAD+ elevation: A 2025 trial found that liposomal NMN at 350 mg significantly outperformed non-liposomal NMN at the same dose — delivery format matters as much as quantity.
• For sleep quality: A 12-week trial with 250 mg/day in adults aged 65–75 found significantly improved sleep quality and maintained walking speed.

Most human trials have used 250–500 mg/day as the primary dose range. There is no established optimal dose as of 2026. Individual factors including age, weight, existing NAD+ levels, and metabolic health likely influence response significantly.

---

NMN Safety: What We Know So Far

Across all human trials published to date, NMN has shown a consistent and reassuring safety profile. No serious adverse events have been attributed to NMN supplementation at any dose tested in clinical research.

A 60-day randomized trial found that NMN raised NAD+/NADH levels by 38% compared to baseline, with no meaningful adverse effects and a measurable improvement in quality of life scores. The first human safety study, conducted at Keio University in Japan, found that single oral doses of 100, 250, and 500 mg were all well-tolerated.

Long-term safety data beyond 6 months remains limited. Anyone considering NMN supplementation should discuss it with a qualified healthcare provider, particularly with existing medical conditions or medications.

---

Key Takeaways for Longevity-Focused Supplementation

1. NAD+ decline is real and well-documented. By middle age, NAD+ levels in key tissues have dropped meaningfully, and this decline is causally linked to multiple hallmarks of biological aging.
2. NMN may be a better choice than NR for older or obese adults. The NRK1 enzyme needed to convert NR into NMN is downregulated in both aging and obesity. NMN bypasses this step.
3. NMN's benefits in human trials are real but modest. Walking speed improvements, liver enzyme reductions, and NAD+ elevation are all documented in human RCTs. Dramatic anti-aging effects remain to be proven in long-term large trials.
4. Dose is not linear. More NMN is not always better. For metabolic outcomes, lower doses (≤300 mg) appear more effective. Delivery method (liposomal vs. standard) may matter significantly.
5. Combining NMN with CD38 inhibition may be the future. Blocking the enzyme that breaks down NAD+ while supplying a precursor is more effective than either strategy alone, per the Kyoto University research.
6. Dry eye may be an early warning sign. Age-related dry eye may reflect broader NAD+ depletion — not just a local eyelid problem.

---

Frequently Asked Questions

What is NMN and what does it do?

NMN (nicotinamide mononucleotide) is a naturally occurring compound that your body uses to make NAD+, a coenzyme essential for cellular energy production, DNA repair, and healthy aging. NAD+ levels decline with age, and NMN supplementation is one approach to restoring them.

Is NMN better than NR?

It depends on who is taking it. For younger, lean adults, NR and NMN may be comparably effective. For older adults or people with obesity, a 2026 University of Helsinki study found that the enzyme needed to convert NR into NMN (NRK1) is significantly less active — making direct NMN supplementation potentially more efficient for these populations.

What does NMN do for the liver?

A 2025 meta-analysis of 6 clinical trials found that NMN significantly reduced ALT — a primary marker of liver stress and injury — in middle-aged and elderly adults. The effect was most pronounced in adults under 60 and when NMN was taken for less than 10 weeks.

Does NMN improve muscle function?

Human trials show that NMN improves walking speed, particularly in adults under 60. Grip strength improvements were more modest. One study found that NMN maintained walking speed over time in older adults even when it didn't increase it — preventing the decline seen in placebo groups.

What is the best NMN dosage?

There is no single optimal dose established in research. For metabolic benefits such as insulin sensitivity, 300 mg or less appears most effective. For physical performance and NAD+ elevation, doses from 250–900 mg have shown benefits. Liposomal formulations may raise NAD+ more effectively than standard forms at the same dose.

Is NMN safe?

All human trials to date have found NMN to be well-tolerated without serious adverse effects. Long-term safety data beyond 6 months is limited. NMN should be discussed with a healthcare provider, especially for people with existing health conditions or who take medications.

Can NMN help with dry eye?

A 2026 Kyoto University study found that NMN, when combined with a CD38 inhibitor, reversed age-related oil gland dysfunction in the eyelids of aged mice — the primary cause of age-related dry eye. This research is in early stages and was conducted in animal models.

What is CD38 and why does it matter for NMN?

CD38 is an enzyme that breaks down both NAD+ and NMN. It becomes more active with age and is recruited by inflammation, creating a self-sustaining cycle of NAD+ depletion. Inhibiting CD38 while supplementing with NMN may produce a synergistic effect in raising NAD+ levels more effectively than either approach alone.

Does NMN extend lifespan?

In mice, long-term NMN supplementation has been shown to extend lifespan and delay frailty. In humans, no lifespan data exists yet. The human evidence supports NAD+ elevation and several health markers improving, but longevity outcomes in people remain to be studied in long-term trials.

---

References

1. Lapatto, H. A., et al. (2026). The effect of obesity and aging on NAD+/Sirtuin metabolism transcription and DNA methylation in subcutaneous adipose tissue of monozygotic twin pairs discordant for BMI. International Journal of Obesity. https://doi.org/10.1038/s41366-025-02007-w
2. Hamada, Y., et al. (2026). NAD boosting mediated by CD38 inhibition drives reversal of a pathological vicious cycle of intracrine activity and inflammation in eyelid meibomian gland dysfunction. bioRxiv. https://doi.org/10.64898/2026.02.08.704637
3. Wang, J. P., et al. (2025). Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly. Current Pharmaceutical Biotechnology, 26(13), 2141–2152. https://doi.org/10.2174/0113892010306242240808094303
4. Morifuji, M., et al. (2024). Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults. GeroScience, 46(5), 4671–4688. https://doi.org/10.1007/s11357-024-01204-1
5. Pencina, K. M., et al. (2023). Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults. Journal of Clinical Endocrinology & Metabolism, 108(8), 1968–1980. https://doi.org/10.1210/clinem/dgad027
6. Peclat, T. R., et al. (2022). CD38 inhibitor 78c increases mice lifespan and healthspan in a model of chronological aging. Aging Cell, 21(4), e13589. https://doi.org/10.1111/acel.13589
7. Ratajczak, J., et al. (2016). NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nature Communications, 7, 13103. https://doi.org/10.1038/ncomms13103
8. Rao, et al. (2022). A Multicentre, Randomised, Double Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement). Frontiers in Aging. https://doi.org/10.3389/fragi.2022.851698

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any supplement regimen. Genevityplus.com does not make disease treatment or prevention claims for any product.